BiocurePharm, Korea (BPK) Signs MOU With Symbasis GmbH to Develop CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL)
- Written by Newsfile
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) (CURE or the Company) BiocurePharm, Korea (BPK), a subsidiary of Biocure Technology Inc. (CURE) is pleased to announce that BPK has entered into a MOU with Symbasis GmbH. They have expressed a common interest in developing a CAR-T...